Results at 48 weeks in the TENAYA and LUCERNE phase 3 trials showed positive outcomes of faricimab for neovascular age-related macular degeneration.Dosing intervals were between 12 and 16 weeks in 80% of the patients.“Faricimab is the first bispecific …
Month: September 2021
US Eye Practice Network Expands into North Carolina
ELIZABETH CITY, N.C.–(BUSINESS WIRE)–US Eye has expanded into North Carolina with the addition of Albemarle Eye Center and Precision Eye Care to its network.
Apellis reports mixed results for pegcetacoplan for geographic atrophy
Apellis Pharmaceuticals reported topline results from two phase 3 studies investigating pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release.DERBY and OAKS are multicenter, random…
Global Dry Age-Related Macular Degeneration Market and Competitive Landscape 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Age-Related Macular Degeneration Market and Competitive Landscape – 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Dry Age-Related Macular Degen…
Sungate Cataract, LASIK and Vision Center Joins US Eye Network
HILTON HEAD, S.C.–(BUSINESS WIRE)–Sungate Cataract, LASIK and Vision Center, one of the Lowcountry’s leading multi-specialty ophthalmology groups, has partnered with US Eye.
Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer
PHILADELPHIA–(BUSINESS WIRE)– #biotechnology–Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the appointment of Mahen Gundecha as …
Dry eye candidate demonstrates promising results in phase 2b study
AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals.AR-15512, a TRPM8 agonist, demonstrated positive topline results in COMET-1, a …
Panel: ‘Weak’ evidence supports using medical cannabis to treat chronic pain
An international panel of experts reported that non-inhaled medical cannabis or cannabinoids were associated with modest benefits in patients with chronic pain.Heretofore, most research has focused on the consequences of recreational cannabis use, Jaso…
As telehealth use drops, expert seeks help securing its future
Data from FAIR Health, a nonprofit organization that provides information on health care coverage and insurance, indicate that telehealth use may be dropping after skyrocketing in 2020.According to the organization, the percentage of individual service…
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
OCT, OCT-A show retinal changes in children recovered from COVID-19
An OCT and OCT-A study of pediatric patients recovered from COVID-19 showed that morphological and vascular structural changes in the macula and optic disc may occur, including in eyes that appear normal on biomicroscopy and fundus exam.“The morphologi…
Glaukos, Ivantis settle patent lawsuit
Glaukos and Ivantis have entered into a settlement agreement to terminate a patent infringement lawsuit concerning the Hydrus microstent, according to company press releases.Ivantis will pay Glaukos $60 million in two installments, $30 million by Dec. …
Edgemont Partners Advises Tennessee Retina on its Sale to Retina Consultants of America
NEW YORK–(BUSINESS WIRE)–Edgemont Partners acted as exclusive financial advisor to Tennessee Retina on its Sale to Retina Consultants of America.
Q&A: Women in Medicine Summit offers opportunities to network, cultivate change
This year’s Women in Medicine Summit will be held virtually on Sept. 24 to Sept. 25. The conference identifies barriers that women in medicine face and offers solutions to gender inequity.Summit attendees will hear from a diverse group of speakers abou…
VIDEO: Need for remote monitoring will increase with longer-acting drugs
In this video, Anat Loewenstein, MD, MHA, highlights some of the most interesting points of a symposium on remote monitoring of retinal diseases, held during the virtual Euretina congress.Remote monitoring will be needed even more now because longer-ac…
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported up…
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that …
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce les conclusions positives du Data Safety Monitoring Board (DSMB) de l’étude clinique de Phase I/II PIONEER de GS030 comme traitement optogénétique de la rétinopathie pigmentaire
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME), une société biopharmaceutique dédiée au développement et à la commercialisation des thérapies géniques innovantes pour le traitement de…
First results with THR-149 show promise in treatment of diabetic macular edema
First results with THR-149, a bicyclic peptide inhibitor that targets plasma kallikrein, showed safety and efficacy in treating patients with diabetic macular edema, according to a specialist speaking at the virtual Euretina congress.“THR-149 is a high…